Personalized vaccine takes on head and neck cancer in early trial
NCT ID NCT06868433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see if the vaccine boosts the immune system against the cancer. About 40 adults whose cancer can be surgically removed are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized tumor membrane vesicle (TMV) vaccine and pembrolizumab
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced head and neck cancer that has come back or spread.
- What could go wrong
- This is a very early phase 1 trial with only 40 people, so it is mainly checking safety and dosing. The vaccine is personalized and complex, and it may not shrink tumors or work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- Leftover immunotherapy may boost chemo: new study investigates timing
- New drug cocktail shows promise for tough head and neck cancers